Prospective Multi-Institutional Observational Study of Brigatinib In ALK-rearranged advanced NSCLC, (ABRAID Study: WJOG11919L)
Not Applicable
- Conditions
- ALK-rearranged advanced NSCLC
- Registration Number
- JPRN-UMIN000042439
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
Patients for whom the attending physician judged that participation in this clinical study is inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method